“Do not impact fertility.” That was the headline assurance in a February 2021 joint statement⁠ from the American College of ...

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...

Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

A legal filing in Florida accuses pharmaceutical giant Pfizer Inc. PFE and Chairman and CEO Albert Bourla of deceiving ...

If you've been looking for high-yield stocks, Pfizer (PFE-1.40%) may have crossed your radar screen. As shares of the pharma ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common ...

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return ...

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...

Florida Attorney General James Uthmeier filed a lawsuit Thursday against Pfizer Inc., alleging unfair and deceptive marketing ...